#IMUX
November 9, 2026 at 2:15 PM
$IMUX — Press Release

Immunic, Inc. (Nasdaq: IMUX) furnished under Regulation FD a presentation for its Progressive Multiple Sclerosis (PMS) Research and Development Day webinar held November 5, 2026 from 12:30 to 2:00 p.m.

🧵 continued ↓
November 5, 2026 at 10:01 PM
🚨 $IMUX
On November 5, 2026, Immunic, Inc. is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar . The PMS R&D Day will take place on Thursday, November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference.
SEC Filing: IMUX
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 2:03 PM
Immunic ($IMUX) – 13G holder adds

• Holder: Aberdeen
• Stake: 6.05% → 7.99% (about $8M)
• Shares: 824,393 → 1,090,427
• Filed: Nov 2 · Schedule 13G/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks #13G #ElixStocks
Aberdeen Group plc: 7.99% of Immunic ($IMUX)
Schedule 13G/A filed Nov 2. Who filed, the stake, and how it changed.
elixstocks.com
November 2, 2026 at 1:49 PM
#$IMUX weekly close $7.51 (+1.3% w/w), below SMA50 $10.25 / below SMA200 $11.50, RSI 40.3. Support $6.35, resistance $8.60. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/immunic-stoc...
October 31, 2026 at 6:22 AM
#$IMUX weekly close $7.51 (+1.3% w/w), below SMA50 $10.25 / below SMA200 $11.50, RSI 40.3. Support $6.35, resistance $8.60. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/immunic-stoc...
October 31, 2026 at 6:22 AM
#$IMUX virtual progressive MS R&D Day: Thu Nov 5, 12:30 p.m. ET. Close $7.80 (Oct 29), RSI 43, 20d range $6.35-$8.87.
imux.com/immunic-to-h...
www.merlintrader.com/immunic-stoc...
October 30, 2026 at 3:04 PM
#$IMUX virtual progressive MS R&D Day: Thu Nov 5, 12:30 p.m. ET. Close $7.80 (Oct 29), RSI 43, 20d range $6.35-$8.87.
imux.com/immunic-to-h...
www.merlintrader.com/immunic-stoc...
October 30, 2026 at 3:04 PM
$IMUX climbed 2.6% to $7.41 on Friday, below both the 50-day SMA ($11.12) and the 200-day ($10.92), in the lower part of its 20-day range ($6.35-$9.94). Daily RSI 36.
$SPY $XBI. Not investment advice.

Bull/bear scenarios on JC Just Charts: https://justcharts.merlintrader.com/#IMUX
October 26, 2026 at 9:24 AM
Raymond James, Cantor, BofA and Citizens issue positive ratings on #$CAMP, #$BNTC, #$IMUX, #$PHVS and #$MBOT, citing clinical catalysts and upside. notreload.xyz/xy/positive-...
Positive Initiations on CAMP, BNTC, IMUX, PHVS and MBOT
Analysts see attractive risk/reward in Camp4’s SYNGAP1 program, Benitec’s gene therapy, Immunic’s MS trials, Pharvaris and Microbot’s robotic system.
notreload.xyz
October 23, 2026 at 12:13 PM
$IMUX Latest company news, Oct 21, 2026: at MSToronto 2026, CALLIPER open-label extension data for vidofludimus calcium supported the durability of disability outcomes. Exploratory analyses.

https://www.merlintrader.com/immunic-stock-hub/
Immunic $IMUX: Vidofludimus, ENSURE And Cash
Immunic’s vidofludimus calcium program explained: ENSURE, CALLIPER, scientific evidence, cash runway, warrants and the next MS catalysts.
www.merlintrader.com
October 21, 2026 at 4:40 PM
#IMUX Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSTo…

https://www.stocktitan.net/news/IMUX/immunic-presents-new-clinical-biomarker-and-preclinical-data-for-mx1w9ep9v2nn.html?utm_source=stocktitan-bluesky&utm_medium=social
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic (IMUX) is presenting new clinical, biomarker and preclinical findings for investigational vidofludimus calcium in four posters at MSToronto2026.Phase 2 CALLIPER extension analyses showed maintained favorable disability trends among patients continuing treatment; 6.5% discontinued through January 27, 2026. Exploratory analyses found reduced Epstein-Barr virus-specific immune signatures, with reductions associated with improved processing-speed scores. Post-hoc disability analyses favored treatment over placebo, while preclinical findings suggested neuronal protection requiring Nurr1, a protein involved in gene regulation. CALLIPER did not meet its primary brain-volume endpoint.Immunic expects to initiate Phase 3 testing in progressive multiple sclerosis later in 2026 and report top-line results from its fully enrolled Phase 3 ENSURE trials in relapsing multiple sclerosis by year-end 2026.
www.stocktitan.net
October 21, 2026 at 11:00 AM
Latest company news, October 19, 2026: Immunic appointed Jaa Roberson as Chief People Officer, a newly created role, ahead of the pivotal Phase 3 ENSURE read-out expected by the end of 2026. $IMUX

https://www.merlintrader.com/immunic-stock-hub/
Immunic $IMUX: Vidofludimus, ENSURE And Cash
Immunic’s vidofludimus calcium program explained: ENSURE, CALLIPER, scientific evidence, cash runway, warrants and the next MS catalysts.
www.merlintrader.com
October 19, 2026 at 11:16 PM
Immunic #$IMUX: Vidofludimus, ENSURE And Cash

Free Biotech Catalyst Calendar on Merlintrader.

www.merlintrader.com/immunic-stoc...
October 18, 2026 at 6:44 AM
🚨 $IMUX
Nagel Robert Thorvald () reported special transactions (Non-P/S).
SEC Filing: IMUX
Click to view the official SEC document.
www.sec.gov
September 19, 2026 at 1:01 AM
🚨 $IMUX
Analysis Error
SEC Filing: IMUX
Click to view the official SEC document.
www.sec.gov
September 18, 2026 at 11:48 PM
Me, I'm going' to Polynesia.

www.youtube.com/watch?v=ImUx...
Goin' to Polynesia
YouTube video by Michael Hurley - Topic
www.youtube.com
September 14, 2026 at 12:35 PM
🚨 $IMUX
Exhibit Number Description 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SEC Filing: IMUX
Click to view the official SEC document.
www.sec.gov
September 11, 2026 at 9:25 PM
IMUX (IMUX) valuation analysis: fair value, price target, P/E, EV/EBITDA, and EV/Revenue. Full breakdown at tickzen.app. Educational content only — not financial advice.
September 10, 2026 at 5:20 PM